Chimerix (NASDAQ:CMRX) is set to post its quarterly earnings results before the market opens on Wednesday, February 28th. Analysts expect Chimerix to post earnings of ($0.49) per share for the quarter.
Chimerix (CMRX) opened at $4.93 on Tuesday. Chimerix has a 12-month low of $4.17 and a 12-month high of $6.64. The firm has a market capitalization of $232.34, a P/E ratio of -3.45 and a beta of 1.42.
In other news, insider Linda M. Richardson sold 19,833 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $4.47, for a total transaction of $88,653.51. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3224409/chimerix-cmrx-to-release-quarterly-earnings-on-wednesday.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.